In 2018, the same authors reported that treatment with flubendazole (Flu) (Table 1), a potent anthelmintic agent with antiproliferative activity in various types of cancer [73], induced apoptosis concomitant with a significant decrease in the activation status of p95HER2, HER2, HER3, Akt and HER2/HER3 heterodimers in both trastuzumab-susceptible (BT474 and SKBR3) and trastuzumab-refractory (JIMT-1 and MDA-MB-453) HER2+ BC cells [49]. Here, ERBB3 is linked to breast cancer.